Endocrine 89 , 3038 (2025)
Still in clinical trials, this triple agonist has shown remarkable results in early studies
Data presented herein support a novel mechanism dependent on metabolic adaptations observed after a longer time period, which is consistent with previously identified delayed phase of gene expression changes mediated via HIF-1 16
The reduction of roGFP2(S 2 ) is therefore a good example for an enzyme using an alternative reaction pathway to overcome a kinetic challenge, and we hypothesize that other non-glutathione disulfide substrates with reactive proximal cysteinyl residues and rather negative redox potentials also require a ternary complex for their reduction
These results have made these drugs incredibly popular and lucrative for the companies that produce them so it is no surprise that the marketing campaigns for these agents are aggressive
Life gets chaotic, routines break, and suddenly you realize you are a day or two past your scheduled injection